Literature DB >> 19118098

Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats.

Bing S Huang1, Roselyn A White, Arco Y Jeng, Frans H H Leenen.   

Abstract

In Dahl salt-sensitive (S) rats, high salt intake increases cerebrospinal fluid (CSF) Na(+) concentration ([Na(+)]) and blood pressure (BP). Intracerebroventricular (ICV) infusion of a mineralocorticoid receptor (MR) blocker prevents the hypertension. To assess the role of aldosterone locally produced in the brain, we evaluated the effects of chronic central blockade with the aldosterone synthase inhibitor FAD286 and the MR blocker spironolactone on changes in aldosterone and corticosterone content in the hypothalamus and the increase in CSF [Na(+)] and hypertension induced by high salt intake in Dahl S rats. After 4 wk of high salt intake, plasma aldosterone and corticosterone were not changed, but hypothalamic aldosterone increased by approximately 35% and corticosterone tended to increase in Dahl S rats, whereas both steroids decreased by approximately 65% in Dahl salt-resistant rats. In Dahl S rats fed the high-salt diet, ICV infusion of FAD286 or spironolactone did not affect the increase in CSF [Na(+)]. ICV infusion of FAD286 prevented the increase in hypothalamic aldosterone and 30 mmHg of the 50-mmHg BP increase induced by high salt intake. ICV infusion of spironolactone fully prevented the salt-induced hypertension. These results suggest that, in Dahl S rats, high salt intake increases aldosterone synthesis in the hypothalamus and aldosterone acts as the main MR agonist activating central pathways contributing to salt-induced hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118098     DOI: 10.1152/ajpregu.90903.2008

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  42 in total

Review 1.  Central neuromodulatory pathways regulating sympathetic activity in hypertension.

Authors:  Alexander Gabor; Frans H H Leenen
Journal:  J Appl Physiol (1985)       Date:  2012-07-05

2.  Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Authors:  Scott B Hoyt; Whitney Petrilli; Clare London; Gui-Bai Liang; Jim Tata; Qingzhong Hu; Lina Yin; Chris J van Koppen; Rolf W Hartmann; Mary Struthers; Tom Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Tian-Quan Cai; Sloan Stribling; Lee-Yuh Pai; Xiuying Ma; Joe Metzger; Andreas Verras; Daniel McMasters; Qing Chen; Elaine Tung; Wei Tang; Gino Salituro; Nicole Buist; Joe Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Maxwell; Mike Lassman; Theresa McLaughlin; Jose Castro-Perez; Daphne Szeto; Gail Forrest; Richard Hajdu; Mark Rosenbach; Yusheng Xiong
Journal:  ACS Med Chem Lett       Date:  2015-07-17       Impact factor: 4.345

Review 3.  Central mineralocorticoid receptors, sympathetic activity, and hypertension.

Authors:  Frances McManus; Scott M MacKenzie; E Marie Freel
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 4.  The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction.

Authors:  Bing S Huang; Frans H H Leenen
Journal:  Curr Heart Fail Rep       Date:  2009-06

Review 5.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

6.  Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Authors:  Scott B Hoyt; Min K Park; Clare London; Yusheng Xiong; Jim Tata; D Jonathan Bennett; Andrew Cooke; Jiaqiang Cai; Emma Carswell; John Robinson; John MacLean; Lindsay Brown; Simone Belshaw; Thomas R Clarkson; Kun Liu; Gui-Bai Liang; Mary Struthers; Doris Cully; Tom Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Tian-Quan Cai; Sloan Stribling; Lee-Yuh Pai; Xiuying Ma; Joe Metzger; Andreas Verras; Daniel McMasters; Qing Chen; Elaine Tung; Wei Tang; Gino Salituro; Nicole Buist; Jeff Kuethe; Nelo Rivera; Joe Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Maxwell; Mike Lassman; Theresa McLaughlin; Jose Castro-Perez; Daphne Szeto; Gail Forrest; Richard Hajdu; Mark Rosenbach; Amjad Ali
Journal:  ACS Med Chem Lett       Date:  2015-04-07       Impact factor: 4.345

7.  Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.

Authors:  Ryan M Downey; Masaki Mizuno; Jere H Mitchell; Wanpen Vongpatanasin; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

Review 8.  Mineralocorticoid Receptors, Neuroinflammation and Hypertensive Encephalopathy.

Authors:  Maria Elvira Brocca; Luciana Pietranera; Edo Ronald de Kloet; Alejandro Federico De Nicola
Journal:  Cell Mol Neurobiol       Date:  2018-08-16       Impact factor: 5.046

Review 9.  Mineralocorticoid Antagonism and Diabetic Kidney Disease.

Authors:  Yuliya Lytvyn; Lucas C Godoy; Rosalie A Scholtes; Daniël H van Raalte; David Z Cherney
Journal:  Curr Diab Rep       Date:  2019-01-23       Impact factor: 4.810

10.  Aldosterone synthesis in the brain contributes to Dahl salt-sensitive rat hypertension.

Authors:  Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Maria Plonczynski; Celso E Gomez-Sanchez
Journal:  Exp Physiol       Date:  2009-10-16       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.